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Abstract
HCV (hepatitis C virus) research, including therapeutics and vaccine development, has been hampered by the lack of
suitable tissue culture models. Development of cell culture systems for the growth of the most drug-resistant HCV genotype
(1b) as well as natural isolates has remained a challenge. Transfection of cultured cells with adenovirus-associated RNAI (VA
RNAI), a known interferon (IFN) antagonist and inhibitor of dsRNA-mediated antiviral pathways, enhanced the growth of
plasma-derived HCV genotype 1b. Furthermore, persistent viral growth was achieved after passaging through IFN-a/b-
deficient VeroE6 cells for 2 years. Persistently infected cells were maintained in culture for an additional 4 years, and the
virus rescued from these cells induced strong cytopathic effect (CPE). Using a CPE-based assay, we measured inhibition of
viral production by anti-HCV specific inhibitors, including 29-C-Methyl-D-Adenosine, demonstrating its utility for the
evaluation of HCV antivirals. This virus constitutes a novel tool for the study of one of the most relevant strains of HCV,
genotype 1b, which will now be available for HCV life cycle research and useful for the development of new therapeutics.
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Introduction
Hepatitis C virus (HCV), a member of the Flaviviridae family, is
an enveloped, positive-sense RNA virus that infects approximately
170 million people worldwide. Chronic HCV infection can lead to
serious liver disease, including cirrhosis and hepatocellular carcino-
ma. Current therapy with pegylated interferon (IFN) and ribavirin is
expensive, associated with serious side effects and only effective in
about 50% of treated patients. Of the six major genotypes of HCV,
the relatively IFN-resistant genotypes 1a and 1b predominate in the
United States, Japan and Western Europe [1].
Recent developments have advanced the HCV research field
whereby a single virus isolate (cloned from a patient with a rare
case of fulminant hepatitis C), JFH-1, or derivatives of that isolate
have been shown to robustly replicate in the human hepatoma cell
line, Huh7 [2,3]. Full-length replicons constructed by adding the
structural coding regions from another genotype 2a virus, J6 [2],
were shown to not only replicate in culture, but to efficiently
produce infectious viral particles [2–6]. Replication of the J6/JFH-
1 virus in Huh7 cells was more robust in a derivative cell line,
termed Huh7.5, which was selected from replicon-containing
Huh7 cells after curative treatment with IFN [6,7]. An infectious
system based on the use of a Vero cell line and the pHCV-WHU-1
consensus clone (genotype 1b) was reported to produce high levels
of HCV genome (.10
8 copies/ml) with the aid of T7 polymerase
provided by recombinant vaccinia virus vTF7-3 [8].
While the current cell culture systems utilize viruses that were
initially replicon-derived from the JFH-1 isolate [2–4,9–15], from
HCV genotype 1b consensus clones [8,16] or from the HCV
genotype 1a prototype virus (H77-S) [10], there remains the need
for a system that would be permissive for a wide variety of HCV
strains found in nature. Human hepatocytes (including fetal
hepatocytes) have been reported to support virus replication after
RNA transfection or infection with patient sera [17,18]. However,
the use of primary cells has several technical limitations because
they proliferate poorly in vitro and divide only a few times. Primary
cultures could be maintained for longer periods of time only if the
cells were immortalized by introducing oncogenes, a procedure
that typically results in changes of the hepatocyte characteristics
and function [17].
One approach to overcoming the obstacle of limited HCV
growth in culture is to identify the mechanism of restriction.
Activation of alpha/beta interferon (IFN-a/b) production is a key
step in the innate response to viral infection and to the presence of
double-stranded RNA (dsRNA) synthesized during replication of
many viruses [19]. Several cellular dsRNA-binding proteins have
been implicated in the IFN-response to infection. For instance, we
have previously identified the adenosine deaminase that acts on
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inhibitor of HCV replicon growth in cell culture [20]. ADAR1
converts adenosines in viral RNA to inosine [21], rendering the
RNA inactive [20]. Both ADAR1 and the IFN-induced dsRNA-
activated protein kinase (PKR) are inhibited by the small
adenovirus-associated RNA (VA RNAI) [20,22,23]. When VA
RNAI is transfected into replicon containing Huh7 cells, it
increases replication by 40-fold [20], suggesting that these IFN-
induced proteins impose critical limitations to HCV replication.
In this study, we achieved growth of an HCV genotype 1b
isolate by inoculating IFN-deficient cells with human plasma from
an infected patient. Viral replication was stimulated further with
the addition of VA RNAI, and led to the creation of a cell line
persistently infected with HCV. More interestingly, the virus
isolated from these cultures has the potential to induce cytopathic
effects in the persistently infected VeroE6 cells and cause massive
cell death in Huh7.5 cells.
Results
Construction of a persistently infected cell line, LB-piVe
Based on our previous finding that VA RNAI enhanced HCV
replication in the replicon system [20], we hypothesized that virus
growth in cell culture may also be inhibited by IFN-induced
pathways. Our approach was to employ VeroE6 cells, which
contain a homozygous-allelic deletion of the IFN-a/b genes
[24,25], yet retain the ability to express IFN-induced genes such us
ADAR1 and PKR, which can be activated during virus infection.
Cells were transfected with a plasmid encoding VA RNAI (pVA;
[26,27]), and then inoculated once with HCV genotype 1b
infectious human plasma, LB [28,29] (Figure 1) or with genotype
1a infectious chimpanzee serum [30] (see Text S1 and Table S1).
Normal human serum was used as a negative control. Infected
cells were passaged (division ratio of 1:6) every seven days for 20
weeks with weekly pVA re-transfection (Table 1). HCV RNA was
detected sporadically in the virus-infected cells after week 20.
Nevertheless, passages were continued weekly in the absence of
VA RNAI. Surprisingly, after 2 years of passage in culture in the
absence of VA RNAI, HCV RNA was detected consistently,
indicating that the virus was able to establish a persistent infection.
No virus was detected after 20 weeks in the control experiment
that was infected with normal human serum. The possibility that
the positive PCR results were due to RNA carry-over is extremely
low since the cells had been diluted ,1.94610
96 after 2 years in
culture. LB-plasma persistently infected VeroE6 cells (LB-piVe
cells) were screened with anti-human- and anti-monkey-specific
primers to ensure that the cultures were not contaminated with
human cells (data not shown).
Figure 1. Genotype 1b-persistently infected VeroE6 cells
express HCV antigens. Immunostaining of naı ¨ve VeroE6 (A–D, left
panels) and LB-piVe cells (A–D, right panels). LB-piVe cells (A, C) and LB-
piVe-enriched, panned cells (B, D). (E, F) Immunoblot of LB-piVe and J6/
JFH-1-infected cell extracts, stained with anti-NS5A antibody (E) or anti-
Core antibody (F). (G) HCV RNA extracted from filter-clarified
supernatants from J6/JFH-1-infected Huh7.5 and VA RNAI-transfected
LB-piVe cells, quantitated by real-time PCR. Error bars, 6SD.
doi:10.1371/journal.ppat.1000910.g001
Author Summary
Hepatitis C virus (HCV) causes a persistent infection that
can lead to hepatocellular carcinoma and liver cirrhosis.
Interferon (IFN)-based treatments are ineffective for some
HCV genotypes. HCV research has been hampered by the
lack of suitable cell culture systems. With the discovery of a
unique HCV genotype 2a isolate that can replicate in the
human liver cell line Huh7, some obstacles were overcome.
However, there remains the need of systems to grow IFN-
resistant genotypes and serum-derived isolates. Here we
show that the presence of adenovirus-associated RNAI (VA
RNAI), a known IFN antagonist, permitted establishment of
a persistent infection of genotype 1b in VeroE6 cells that
were passaged weekly for more than 2 years. The
persistent virus induces strong cytopathic effect (CPE), a
feature that allowed the development of a CPE-based
assay to test HCV-specific inhibitors, neutralization by anti-
HCV immunoglobulins and by anti-CD81 antibody, and
HCV-specific siRNA. Our system provides the first persis-
tent culture of genotype 1b virus and a convenient assay
that can be used for therapeutics development.
Table 1. HCV persistent infection in VeroE6 cells.
Week PCR Nested PCR
LB-piVe NC LB-piVe NC
1 22 6 2
2 22 6 2
3 22 + 2
4 22 + 2
5 + 2 + 2
6N D 2 ND 2
7 22 + 2
8 + 2 + 2
9 + 2 + 2
10 + 2 + 2
11 6 2 + 2
12 ND 2 ND 2
13–20 22 2 2
VeroE6 cells were transfected with pVAls6 (encoding VA RNAI) or pcDNA3, and
then infected with genotype 1b-infected human plasma [28,29], at week 0. For
each of 20 weeks the cells were diluted 1:6, split and re-transfected with pVAls6.
Cells were harvested and analyzed weekly for detection of HCV RNA by RT-PCR
(PCR, first 40 cycles) followed by nested PCR [62]. Positive, (+); weakly positive, (6);
negative (2); negative control pcDNA3, (NC); not determined, (ND). The limit of
detection for this assay was evaluated [62] and calculated at 10
3 RNA copies/ml.
doi:10.1371/journal.ppat.1000910.t001
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virus) shares 99.7% amino acid homology with the parental
genotype 1b virus and contains only 10 amino acid changes in the
nonstructural region. Sequences have been deposited into
GenBank. A representative nucleotide sequence of the LB-piVe
virus, aligned with the parental virus sequence and a prototype
genotype 1b virus is shown in Figure S1. The complete sequence
alignment and reverse genetics studies are being conducted and
will be presented for publication in the future.
LB-piVe cells express HCV viral antigens
To visualize HCV antigen expression, we stained LB-piVe fixed
cells with polyclonal anti-HCV serum [30] (Figure 1A and B)o r
anti-NS5A monoclonal antibodies (Figure 1C and D). To
increase the sensitivity of the immunofluorescence assay, we
enriched the cell culture by selecting virus-containing, antigen-
expressing cells (Figure 1B and D) using a cell panning
procedure (see Materials and Methods). LB-piVe cells expressed
HCV antigens in both perinuclear and cytoplasmic regions of the
cells as expected (Figure 1A–D, right panels). The results
suggest that the addition of VA RNAI may broaden cellular
tropism by allowing persistent growth and replication of HCV
from plasma in non-hepatic VeroE6 cells.
Western blot analysis of LB-piVe (after two rounds of cell panning)
and J6/JFH-1-infected cell extracts demonstrates that HCV proteins
were expressed at detectable levels (Figure 1E and F). Because the
proportion of immunofluorescent cells was low, we then compared
the levels of viral RNA in filter-clarified supernatants from LB-piVe
panned cells versus J6/JFH-1-infected Huh7.5 cells (Figure 1G). J6/
JFH-1 yielded 9.2610
7 RNA copies/ml, while LB-piVe yielded
1610
4 RNA copies/ml; (see Figure 1G). Persistent infection could
only be maintained at a low viral titer, as attempts to obtain the
higher viral yields by cell panning (Figure 1B and D)r e s u l t e di n
viral instability due to cell cytolysis (data not shown).
Quantitation of viral titers by a CPE (cytopathic effect)-
based assay
Interestingly, we observed evidence of CPE in LB-piVe cells
after 2 years in culture (Figure 2A, right). To demonstrate that
the virus from the persistently-infected cells was infectious, filter-
clarified culture supernatants from LB-piVe cells were used to
inoculate naı ¨ve Huh7.5 cells. The infected Huh7.5 cells demon-
strated enhanced CPE compared to the parental LB-piVe cells,
and resulted in gross cell death after 5 days (Figure 2B, right).
Viral antigens were detected at 3 days post-transfer of superna-
tants by immunostaining the infected Huh7.5 cells (Figure 2C,
right) and also by immunoblotting Huh7.5 cell extracts
(Figure 2D) with anti-NS5A antibody. The level of CPE observed
in Huh7.5 cells (Figure 2E, micrographs) was directly related
to the amount of viral RNA in the inoculum (Figure 2E,
histogram). Taken together, our results show that viral infectivity
can be transferred from the persistently infected cell line, LB-piVe,
to naı ¨ve hepatic cells and that the level of CPE correlates with the
level of input viral RNA.
Based on these unique characteristics of LB-piVe, we developed
a CPE-based end-point dilution assay for quantification of viral
titers. Naı ¨ve Huh7.5 cells were plated in 96-well plates and then
infected with serial dilutions of virus-containing filter-clarified
supernatants (see Materials and Methods). Five days post-infection
(dpi), cells were observed by light microscopy and those wells
showing CPE were assigned a positive result. The 50% tissue
culture infectious dose (TCID50) was calculated using the method
of Reed and Muench [31].
Virus neutralization
To further confirm that the CPE was linked to virus infection,
we employed the end-point dilution assay (based on visualization
of cell death) to study virus neutralization. Huh7.5 cells were first
incubated with antibodies to the putative viral receptor CD81 [32–
34] and then infected with serial dilutions of filter-clarified
supernatants of LB-piVe (Figure 3A) or J6/JFH-1 (Figure 3B).
Viral titers were determined as described in Materials and
Methods. This study showed that anti-CD81 antibodies reduced
genotype 1b LB-piVe viral titers by ,16log10 (Figure 3A),
similar to that observed for the genotype 2a virus J6/JFH-1
(Figure 3B). Pre-incubation of LB-piVe virus with HCV-specific
immunoglobulin intravenous (HCIGIV) [35] (Figure 3C) or anti-
E2 monoclonal antibodies [36] (Figure 3D) also inhibited virus
Figure 2. HCV growth can be measured by observing cytopathic effects. Light microscopy of (A) mock-infected VeroE6 (left panel) and LB-piVe cells
(right panel) and (B) crystal violet-stained Huh7.5 cells 5 days after transfer of supernatant from A. (C) Mock-infected (left panel) and LB-piVe-infected Huh7.5
cells (from B, right panel) immunostained with anti-Core antibodies at 3 dpi. (D) Immunoblot of BB7 replicon containing Huh7.5 cells or LB-piVe-infected
Huh7.5 cell extracts, stained with anti-NS5A antibody. (E) Histogram showing quantitative RNA titer (HCV RNA copies/ml, see Materials and Methods for
details on HCV RNA quantification) and corresponding micrographs of crystal violet stained LB-piVe-infected Huh7.5 cells at 5 dpi (mag 2006).
doi:10.1371/journal.ppat.1000910.g002
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JFH-1 with normal IGIV or an isotype-matched negative control
antibody did not affect viral titers. It may be noted that the anti-E2
monoclonal antibodies were generated to genotype 1a recombi-
nant E2 proteins, including the hypervariable region. Conse-
quently, their ability to neutralize a genotype 1b virus could be
limited to some extent as reflected by the 60% decrease in viral
titers observed. These neutralization experiments demonstrate that
Huh7.5 cell death resulted from the transfer of virus from the LB-
piVe cells, and that infection and viral spread in Huh7.5 cells was
blocked by the addition of HCV-specific antibodies.
We then explored the utility of the CPE-based assay to screen
therapeutics by treating virus-infected cells with HCV inhibitors.
We used a well characterized inhibitor of the HCV polymerase,
29-C-Methyl-D-Adenosine (29-C-Me-A) [37]. J6/JFH-1 and LB-
piVe infected cells were incubated with complete growth medium
containing a range of 29-C-Me-A, from 0.05 to 1 mM. Titers were
determined as described in Materials and Methods. The results
showed that LB-piVe growth was reduced after treatment with 29-
C-Me-A (Figure 4A), with a 50% effective concentration (EC50)
value in the nanomolar range, comparable to that observed for J6/
JFH-1 (Figure 4B). Additionally, we tested an HCV-specific small
inhibitory RNA to knock-down viral titer (siRNA 313; [38], for
details see Materials and Methods). In this assay, siRNA 313
inhibited CPE caused by LB-piVe virus by ,80% (Figure 4C),
while J6/JFH-1 was inhibited by .90% (Figure 4D).
When LB-piVe cells were treated with IFN, the virus continued
to replicate. We measured LB-piVe viral titers in cells that were
treated with 0, 10, 100 or 1000 IU/mL of IFN for 24, 48 and 72 hr
(Figure 4E). LB-piVe titer decreased slightly only at 72 hr with
100 or 1000 IU/mL, but the values were not significantly lower
than for 48hr. In contrast, J6/JFH-1 titer decreased by 5-fold when
treated with 10 IU/mL for 48 hr and there was no detectable virus
with 1000 IU/mL (Figure 4F). To ensure that the LB-piVe cells
had not become insensitive to IFN treatment, we measured LB-
piVe titers in Huh7.5 cells that were also treated with IFN
(Figure 4G). There was no significant effect on LB-piVe titers by
treating the Huh7.5 cells with IFN for 5 days at 10 IU/mL and no
change after treatment with 1000 IU/mL. A decrease of 0.2 log10
was observed when comparing 10 IU/mL vs 1000 IU/mL over 5
days (Figure 4G). This small difference may be attributed to the
long incubation period. These results indicate that the LB-piVe
virus and not the persistently infected cells are relatively IFN
resistant as would be expected for a natural genotype 1b virus
isolate. To ensure that the virus had not acquired IFN resistance
through passage in culture, we compared the effects of IFN
treatment on the parental virus (LB) with the persistent virus in
VeroE6 cells (Figure 4H). There was little effect after treating the
LB virus for 24, 48 or 72 hr, demonstrating that this parental
genotype 1b strain was relatively IFN resistant, as expected.
These inhibition studies demonstrated that the LB-piVe virus
was sensitive to HCV-specific inhibitors and that the CPE-based
assay provides an easy and quantitative method for measuring the
efficacy of antiviral compounds. Furthermore, the LB-piVe virus
behaved like the wild-type parental virus and maintained its
relative IFN resistance.
Limitations on HCV growth are alleviated by VA RNAI
VeroE6 cells express the putative receptors for HCV [39]. To
elucidate the general growth properties of HCV in these cells, we
tested their ability to support replication of the IFN-sensitive
genotype 2a virus (Figure 5). Cells were mock infected
(Figure 5A and B, left) or J6/JFH-1-infected (Fig. 5A and B,
right), and immunostained at 4 dpi with anti-NS5A antibody. J6/
JFH-1 was infectious and replicated in many Huh7.5 cells
(Figure 5B, right) and fewer VeroE6 cells (Figure 5A, right).
An increase in the number, size and intensity of the foci in J6/
JFH-1-infected Huh7.5 cells was observed in the presence of wild-
type VA RNAI (WT) (Figure 5C, right panel) but not mutant
VA RNAI (dl1) (Figure 5C, center panel), demonstrating that
J6/JFH-1 growth was improved by VA RNAI. These data suggest
that while the paracrine and autocrine IFN pathways may be
defective in VeroE6 cells, additional cellular factors antagonized
by VA RNAI are limiting for HCV growth. We also determined
the viral titer of the J6/JFH-1-infected Huh7.5 cells, which were
transfected with mutant VA RNAI (dl1) or wild-type VA RNAI
(WT) (Figure 5D). The results showed that wild-type VA RNAI
led to an increase in J6/JFH-1 viral titers by .1.5 log units
(Figure 5D, WT), and further confirms that VA RNAI enhances
both growth and replication of this genotype 2a virus, probably
through inhibition of dsRNA-activated pathways.
The amount of J6/JFH-1 RNA was quantitated (relative to
GAPDH) by real-time RT-PCR. Replication of J6/JFH-1
increased by 15-fold (63-fold SEM) in Huh7.5 cells with VA
RNAI, whereas VeroE6 cells containing VA RNAI yielded 7-fold
(62-fold SEM) more viral RNA than cells with mutant (dl1) VA
RNAI (Figure 5E). While the exact mechanism is unknown, a 15-
fold increase in viral RNA suggests that the fate of viral RNA in
the cells may be affected by the presence of VA RNAI, consistent
with our previous findings that ADAR1 was inhibited in replicon
cells containing VA RNAI [20]. J6/JFH-1 RNA titers were
enhanced by VA RNAI twofold in Huh7.5 cells (Figure 5E, left)
over VeroE6 cells (Figure 5E, right), illustrating preferential
growth of J6/JFH-1 in Huh7.5 cells and demonstrating that HCV
genotype 2a growth, in addition to genotypes 1a and 1b, is
enhanced by VA RNAI.
VA RNAI may increase HCV replication through RNA
stability
VA RNAI allowed the establishment of a persistently infected
cell line and increased growth of LB-piVe (Figure 6A) and J6/
Figure 3. Virus neutralization by anti-CD81 and anti-HCV
antibodies. (A) Huh7.5 cells were pre-incubated with anti-CD81
before infection with filter-clarified supernatants from LB-piVe cells or
(B) J6/JFH-1-infected cells. M2, isotype-control antibody. J6/JFH-1 was
titrated by an end-point dilution assay using indirect immunofluores-
cence. Wells were scored positive if at least 1 positive cell was detected.
(C) LB-piVe was neutralized by incubation with human anti-HCIGIV [35]
or (D) anti-E2 monoclonal antibodies [36]. LBpiVe virus titers in A, C and
D were determined by a CPE-based TCID50 assay. HCV titers were
calculated using the method of Reed and Muench [31]. Error bars, 6SD.
doi:10.1371/journal.ppat.1000910.g003
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parental virus during the first few days of infection, we examined
its effect on HCV RNA stability by comparing the relative increase
in viral RNA in VeroE6 cells to that in Huh7.5 cells that were
inoculated with the same HCV-positive human plasma (LB,
[28,29]) that was used to establish the persistently infected cell line
LB-piVe. Naı ¨ve VeroE6 and Huh7.5 cells were transfected with
pVA before inoculation with LB plasma (transient infection)
(Figure 6B–D). RNA was extracted from cell lysates on the days
indicated (Figure 6B, C) and HCV RNA was measured by
quantitative RT-PCR. The relative amount of HCV RNA in
pVA-transfected cells versus pVA-untransfected cells (Figure 6B)
increased 60-fold after 8 days of transient infection in VeroE6
cells. However, in transiently infected Huh7.5 cells, the relative
amount of HCV RNA did not increase with the addition of VA
RNAI over 8 days (Figure 6B), consistent with our inability to
obtain a persistently infected Huh7.5 cell line. It may be noted
here that the CT values of GAPDH employed as a normalization
control in these experiments, were consistent among cells in the
presence or absence of pVA. Thus, the dramatic increase in viral
RNA in VeroE6 cells may be due to factors other than the
variation in transcript levels of GAPDH reported in liver cells [40–
43]. Furthermore, when the results were expressed in terms of
absolute HCV RNA copy number (using an HCV RNA standard
curve and measuring copies per ml; Figure 6C), the number of
RNA copies remained stable in Huh7.5 cells, suggesting that the
level of replication may be equal to the degradation of HCV RNA,
with or without the addition of VA RNAI. In contrast, a
precipitous decline in HCV RNA copy number was observed in
transiently infected VeroE6 cells in the absence of VA RNAI,
while the levels remained relatively stable in cells that contained
VA RNAI (Figure 6C), thus indicating that VA RNAI has an
effect on viral RNA over 8 days in VeroE6 cells. We speculate that
this effect may be due to; (i) altering the RNA synthesis rate, (ii)
altering the degradation rate of HCV RNA molecules other than
the input RNA, or (iii) inhibition of an RNA degradation pathway.
Incubation of transiently infected cells with an RNA polymerase
inhibitor helped to assess the level of viral RNA in the absence of
viral replication. We treated the parental virus with 29-C-Me-A,
which resulted in similar HCV RNA levels when cells were
transfected with either WT- or mutant-VA RNAI (Figure 6D).
Initially there was a decrease in viral RNA (time 0=input RNA).
VA RNAI was not able to stimulate replication in the presence of
an inhibitor of HCV polymerase. Additionally, the level of viral
RNA did not increase in the presence of wild-type VA RNAI,
suggesting that viral RNA stability was also not affected by the
presence of VA RNAI in the absence of replication. Figure 6 shows
that in the presence of VA RNAI, viral RNA titer goes down and
then levels off; while in the absence of wild-type VA RNAI it
continues to decrease (Figure 6C). When the experiment is done in
the presence of 29,C-Me-A, the RNA titer decreases and levels off,
independent of VA RNAI (Figure 6D). This is consistent with the
mechanism of 29,C-Me-A, which inhibits new RNA synthesis,
however, in this experiment the viral RNA is not degraded 100-
fold (c.f., Figure 6C and 6D). We interpret these data as follows: 1)
in the absence of viral replication (in 29,C-Me-A-treated cells),
there is less degradation of the viral RNA; 2) in the absence of viral
replication (in 29,C-Me-A-treated cells) there is also the absence of
dsRNA (positive strand plus negative strand); and 3) therefore,
dsRNA-activated proteins, including ADAR1, would not be
activated, leaving VA RNAI with no effect on stability. This is
consistent with our ongoing studies that show that only wild-type
VA RNAI (that which can bind PKR or ADAR1) is capable of
stimulating the replicon (Taylor, unpublished results). Taken
together, these results suggest that VA RNAI in the early stages of
infection may affect the stability of the viral RNA, either by
altering the degradation rate of new HCV RNA molecules or by
inhibition of an RNA degradation pathway that may be
modulated by viral replication. However, we also cannot exclude
the possibility that VA RNAI alters the HCV RNA synthesis rate
in the absence of a polymerase inhibitor.
Discussion
In this study, we have demonstrated that the addition of VA
RNAI, a known IFN antagonist and inhibitor of dsRNA-mediated
antiviral pathways, permitted the persistent growth of a plasma-
derived HCV in a cell line that lacks IFN genes. Most of the
current knowledge of HCV biology and pathogenesis has been
derived from the use of the unique JFH-1 cell culture system,
which now allows the study of the complete virus life cycle,
including entry, assembly and release. The limitation of this
model, however, is that robust viral growth is restricted only to
hepatic-derived cell lines such as Huh7.5 and Huh7 cells [44] and
only by a genotype 2a replicon-derived virus. The establishment of
an alternative model to characterize other HCV genotypes from
infected individuals is still needed and is critical for the
development of efficient viral therapies to control the disease.
By passaging genotype 1b virus-infected VeroE6 cells for 20
weeks in the presence of VA RNAI and more than 2 years without
VA RNAI, we generated a persistently infected cell line that
expresses HCV antigens at levels high enough to be detected by
immunofluorescence and Western blot (Figure 1A–F, Table 1).
We found that the LB-piVe virus is highly cytotoxic, and is capable
of inducing massive Huh7.5 cell death (Figure 2B, C and E);
indicating that the virus produced in the persistently infected cells
is infectious to hepatocytes. CPE could be blocked by antibodies to
CD81 (Figure 3A), by anti-HCV-specific immunoglobulins
(Figure 3C) and by anti-E2 monoclonal antibodies (Figure 3D),
confirming the link between cell death and viral infection. While
neutralization was not as potent using the anti-E2 monoclonal
antibodies, we believe that this may be due to the antibodies being
raised against recombinant genotype 1a proteins. The genotype
Figure 4. Inhibition of HCV by antivirals. (A) LB-piVe cells (B) and J6/JFH1-infected Huh7.5 cells were treated with increasing concentrations of
29-C-Me-A. The EC50 values were evaluated from dose response curves employing GraphPad Prism 3.0 software. (C) Non-specific siRNA (IRR) [64] or
HCV-specific siRNA (313) [38] transfected Huh7.5 cells were inoculated with LB-piVe and stained with crystal violet (left). Filter-clarified culture
supernatants were titrated by a CPE-based end-point dilution assay (right). (D) Non-specific siRNA (IRR) [64] or HCV-specific siRNA (313) [38]
transfected Huh7.5 cells were inoculated with J6/JFH-1 and stained with anti-Core antibodies at 3 dpi (left). Fluorescent foci were counted in triplicate
wells, and titers were calculated as the mean number of foci per ml (FFU/ml, right). (E) LB-piVe cells were transfected with pVA and then treated with
0, 10, 100 and 1000 IU/ml of Universal Type 1 IFN for 24, 48 and 72 hr. Viral titers were determined as in B. (F) Huh7.5 cells were inoculated with J6/
JFH-1 and treated with 0, 10, and 1000 IU/ml of Universal Type 1 IFN for 72 hr. Viral titers were determined by infecting Huh7.5 cells in the absence of
pVA. (G) LB-piVe titers in the absence of pVA, determined in naı ¨ve Huh7.5 cells with (+IFN) or without (2IFN) the addition of 0, 10, and 1000 IU/ml of
Universal Type I IFN to the culture media. (H) Infection of naı ¨ve, non-transfected VeroE6 cells with genotype 1b-infectious human plasma (LB; [28,29])
and treated with 1000 IU/mL IFN. HCV RNA copies were determined per mg of GAPDH RNA. HCV titers were calculated using the method of Reed and
Muench [31]. Error bars, 6SD.
doi:10.1371/journal.ppat.1000910.g004
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may be reflected in loss of epitope recognition, thus explaining the
0.6 log10 decrease in viral titer.
The LB-piVe virus-mediated CPE has the advantage that it can
be assessed visually, and quantified easily and rapidly. This
represents a significant improvement over the current genotype 2a
HCVcc systems that utilize FFU assays, RT-PCR or reporter
assays for quantitation, which are both laborious and time-
consuming [45]. In addition, we have demonstrated the utility of
this system in virus neutralization studies (Figure 3A, C and D)
and in testing virus inhibition by well characterized HCV-specific
antivirals (Figure 4A, C, E and G).
CPE was observed in VeroE6 cells and more-exaggerated CPE
was found when filterable supernatants were used to infect Huh7.5
cells. While it was possible to enhance viral titer by panning the
LB-piVe cells, and effectively increasing the number of virus-
infected cells, the new culture could not survive after several
passages. We suspect that the virus cannot be maintained in a
culture that demonstrates massive CPE, such as that seen in
Huh7.5 cells. This may be the reason that we were unable to
obtain persistently infected Huh7.5 cell line, while VeroE6 cells
can support persistent HCV infection due to a low-level display of
CPE.
HCV- associated cell death has also been reported in Huh7.5.1
cells after infection with JFH-1 when HCV RNA levels reached a
maximum [46]. Gene expression profiling of HCV-infected
Huh7.5 cells showed both the presence of activated caspase-3
and induction of cell death-related genes, suggesting an association
of virus infection with cytopathic effects. Although not yet
resolved, it has been postulated that HCV could mediate direct
apoptosis by deregulating the cell cycle, which may contribute to
liver injury in infected individuals [46]. While still requiring
further studies and more comparisons between human pathology
and cell culture, we suggest that the LB-piVe system may very well
mimic a natural HCV infection in humans and could represent a
useful tool to study the intricate process of viral pathogenesis.
VeroE6 cells were also permissive for replication of genotype 2a
J6/JFH-1 virus [2] (Figure 5A–C). VA RNAI boosted replication
Figure 5. VA RNAI stimulates replication of J6/JFH-1. (A) J6/JFH-1-infected VeroE6 cells and (B) J6/JFH-1-infected Huh 7.5 cells immunostained at
4 dpi with anti-NS5A antibody. Nuclei were visualized using DAPI staining. (C) Huh 7.5 cells (left) transfected with a defective (dl1, center) [26,27] or wild-
type VA RNAI (+VA RNAI, right) [26,27], infected with J6/JFH-1 (center, right) and immunostained with anti-Core antibodies. (D) Titration of J6/JFH-1 from
culture supernatants in C by an end-point dilution assay using indirect immunofluorescence. Wells were scored positive if at least 1 positive cell was
detected. The TCID50 was calculated using the method of Reed and Muench [31]. (E) J6/JFH-1 RNA (relative to GAPDH RNA) in cell lysates from infected
Huh7.5 or VeroE6 cells after transfection with a defective (dl1) or wild-type (WT) VA RNAI [26,27] and quantitated by real-time PCR. Error bars, 6SD.
doi:10.1371/journal.ppat.1000910.g005
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RNA yield (Figure 5D, E). This may be attributable to an
increase in viral RNA stability and possibly reflects the type of
interplay between host and virus. The presence of VA RNAI
allowed for broadened cell tropism by HCV to include non-
hepatic cells (Tables 1 and S1), perhaps due to its ability to
circumvent the IFN-induced antiviral response. The full-extent of
the mechanisms employed by VA RNAI towards overcoming the
negative effects of IFN is currently unknown. VA RNAI is
important to adenovirus infection and confers virus stability in the
presence of IFN and IFN-induced proteins. It has been suggested
that VA RNAI has an effect on HCV RNA stability by inhibition
of the IFN-induced protein, ADAR1 [20]. When we compared the
relative amount of HCV RNA in VA RNAI-transfected cells
versus -untransfected cells (Figure 6B, C) that were infected with
HCV-positive human plasma LB, we observed a 60-fold increase
in VeroE6 cells. Interestingly, a precipitous decline in HCV RNA
was observed in these cells in the absence of VA RNAI
(Figure 6C). Thus, VA RNAI has an effect in the VeroE6 cells,
at least during the first 8 days of infection. We have yet to evaluate
possible defects in the RIG-I pathway observed previously in
Huh7.5 cells and likely to play a role in early infection [47]. The
fact that we did not observe any increase in the relative amount of
HCV RNA in Huh7.5 cells after VA RNAI transfection followed
by infection with the parental genotype 1b serum-derived virus
(Figure 6B and C), was unexpected. We suspect that the
relatively stable amount of viral RNA reflects extremely low viral
replication of the LB virus in Huh7.5 cells. These findings are
supported by the evidence that we could not establish a
persistently infected cell-line with Huh7.5 cells, suggesting that
VeroE6 cells were more permissive for persistent infection,
perhaps due to the lack of IFN genes.
VA RNAI was not able to rescue the virus during 29-C-Me-A
treatment and does not stimulate replication nor does it protect the
virus from an antiviral that targets the HCV polymerase. We used
this RNA polymerase inhibitor to evaluate RNA stability in the
absence of viral RNA replication. Since VA RNAI only increased
the HCV RNA in the presence of viral replication, we believe that
it may perhaps inhibit cellular factors that are activated during
viral replication (e.g., dsRNA-binding proteins) and cause instabil-
ity of the virus. It’s possible that VA RNAI interacted with, and
therefore blocked ADAR1 and PKR pathways. This would be
consistent with our previous findings showing that the HCV
replicon was stimulated by knock-down or inhibition of ADAR1 or
PKR [20]. Additionally, the inhibition of RNA replication
(including loss of negative strand RNA) should inhibit the
formation of dsRNA intermediates, thus avoiding the activation
of dsRNA-activated proteins that can lead to viral instability [48–
54]. Again, we cannot exclude the possibility that VA RNAI
enhanced viral replication in the absence of the polymerase
inhibitor. Taken together, these data suggest that VA RNAI may
possibly contribute to establishing a persistent infection in VeroE6
cells; however, the presence of VA RNAI alone is not enough to
overcome the cellular antiviral response in Huh7.5 cells. IFN-
deficient VeroE6 cells probably provide a more ideal environment
for a virus that is, usually, IFN responsive. We suspect that this
Figure 6. VA RNAI stimulates replication of HCV and increases
RNA stability. (A) LB-piVe cells transfected with pVA (+VA RNAI )o rd l 1
(2VA RNAI). Filter-clarified culture supernatants were collected on days
0, 2, 4 and 6 (post-transfection) for virus titer determination by CPE-
based TCID50 assay. (B) VeroE6 or Huh7.5 cells transfected with pVA or
dl1 and inoculated with genotype 1b-infectious human plasma (LB;
[28,29]). HCV RNA was extracted from cell lysates at the indicated time
points and the copy number was determined by quantitative RT-PCR
using an HCV standard. Values represent the mean relative increase in
HCV RNA relative to GAPDH RNA (+VA RNAI versus 2VA RNAI). (C)
Values in B expressed as log10 HCV RNA copies/ml. The double-ended
arrow indicates the 60 fold difference in B reflected in the HCV RNA
copies. (D) Infection of naı ¨ve, transfected VeroE6 cells with genotype 1b-
infectious human plasma (LB; [28,29]) treated with 29-C-Me-A. HCV RNA
copies were determined per mg of total cellular RNA. Error bars, 6SD.
doi:10.1371/journal.ppat.1000910.g006
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which may actively inhibit HCV replication [20]. Both Huh7.5
cells and VeroE6 cells express PKR and ADAR1, but only the
VeroE6 cells lack the IFN genes that induce these proteins. We
found that even the persistent virus was stimulated by the presence
of VA RNAI, suggesting that some of the dsRNA-activated
proteins were still expressed and were inhibitory to the virus.
In patients, in general, genotype 2 and 3 viruses are more
sensitive to current antiviral therapy than the genotype 1 viruses
[55]. Genotype 1b is thought to be the most IFN resistant and the
most prevalent in North America, Europe and Japan. However,
the HCV replicons (genotype 1b) and J6/JFH1 virus are sensitive
to IFN in cell culture. It is not clear why viruses respond to IFN
differently in vivo versus in vitro. Since HCV grows well in VeroE6
cells, especially when assisted by VA RNAI, we suggest that
endogenous IFNs may limit HCV replication in cell culture.
We suspect that the LB-piVe virus, like the parental LB from
which it was derived, was relatively resistant to IFN (Figure 4E,
H), a property that has not yet been reported in infectious cell
culture (Figure 4G). While it warrants further investigation, it
may be possible that we were able to obtain this virus because VA
RNAI was present in the early stages of infection and inhibited
the antiviral response generated by viral RNA replication. Our
results on the enhancement of virus replication by VA RNAI are
clearly consistent with evasion of the antiviral response, and
correlate with the observation that susceptibility of human
primary hepatocytes to HCV infection could be improved by
impairing expression of other IFN signaling factors such us
interferon regulatory factor-7 (IRF-7) [17]. We suggest that in the
early stages of cell culture infection, before viral proteins are in
sufficient quantity, the innate immune pathways are active and
control infection (RIG-I, PKR, ADAR1, RNaseL, etc.). Howev-
er, once the virus is given a chance to accumulate, it can
overcome these mechanisms of host control, either through the
E2, NS5A or NS3 proteins [56–58].
Our findings have raised some interesting questions. Future
studies with IFN-sensitive viruses, complemented with known
IFN-resistant HCV proteins (such as NS5A and E2) using
sequences from the LB-piVe virus, are planned. Additionally,
the LB-piVe virus will be ideal for evaluating the genes responsible
for conferring IFN resistance. We plan to construct an infectious
clone and a replicon based on this virus with the aim of evaluating
individual genes. At the same time, alignments with the IFN-
resistant parental strain of LB with IFN-sensitive genotype 1b
replicons may enable the identification of important amino acids
that determine IFN resistance. Transient transfection experiments
complementing the IFN-sensitive replicons will be among the
experiments that will provide insights into the identification of the
features that may confer IFN resistance by this genotype 1b virus.
In summary, here we demonstrate that wild-type HCV
genotype 1b viruses from human plasma can replicate in African
green monkey kidney cells, VeroE6, and that replication of viral
genotypes 1a and 2a can be stimulated by the presence of VA
RNAI. This is a new approach to culturing HCV and the first
report of a cell culture system that represents a convenient assay
for studying genotype 1b. This is an improvement in terms of
utility for research, as the virus can be titrated without employing
error-prone, quantitative RT-PCR methods nor arduous immu-
nocytochemistry-based focus forming assays. The availability of
the LB-piVe virus raises an exciting possibility; potentially opening
a new era of HCV research through the use of a new model
system. Moreover, a persistently infected cell line that exhibits
CPE provides a novel assay that may be conducive to high
throughput development and screening of new antivirals.
Materials and Methods
Plasmids
pVA containing the adenovirus 2 virus-associated RNA I (VA
RNAI) sequence, and VA RNAI mutant dl1 (pVAdl1) plasmids,
were provided by M. B. Mathews [26,27].
Cell culture and transfections
VeroE6 cells (ATCC) were maintained in complete Dulbecco’s
modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA)
containing 10% heat-inactivated Fetal Bovine Serum (FBS;
Hyclone) at 37uC with 5% CO2. Huh7.5 cells were provided by
C.M. Rice (Rockefeller University, NY) and maintained in
complete DMEM containing 10% FBS and non-essential amino
acids (Invitrogen). FBS was screened by RT-PCR to ensure the
absence of bovine viral diarrhea virus (BVDV). Multiple lots of
VeroE6 cells were infected to check for reproducibility. Cells were
cultured before transfection in T25 flasks or 6-well plates at a
density to provide an overnight confluence of 35%, and
transfected with 15–30 mg plasmid vector pVA [26,27] using
DMRIE-C per the manufacturer’s specifications (Invitrogen,
Carlsbad, CA).
Hepatitis viruses and titer determination
HCV genotype 1b. Cells transfected with pVA were
inoculated with 200 ml of plasma containing 10
7 RNA copies/ml
from a genotype 1b-infected patient (LB, [28,29]) at week 0. Seven
dpi, cells were divided 1:6 and transferred to T25 flasks. The next
day, cells were transfected with pVA. The passage and transfection
process was repeated, without re-infection, weekly for 20 weeks
(weekly results shown in Table 1). After 20 weeks, cells were
divided 1:6 weekly without transfection or re-infection for two
years. These LB-persistently infected VeroE6 cells were then
known as LB-piVe cells. A cytopathic effect (CPE)-based end-point
dilution assay was developed for quantification of LB-piVe virus
titer. LB-piVe cells were grown for 8 days. Flasks (T75) containing
culture medium were frozen (at 280uC) and thawed 3 times. This
mixture was cleared by centrifugation and subsequent filtering
(0.45 mm), and filter-clarified culture supernatants were obtained.
To measure LB-piVe titers, naı ¨ve Huh7.5 cells were plated at a
density of 5610
3 per well in 96-well plates to obtain 60%
confluence after 24 hr, and then infected with serial dilutions of
filter-clarified supernatants (8 replicates per dilution). Cells were
observed by light microscopy at 5 dpi. Wells showing CPE were
assigned a positive result. Alternatively, cells were fixed and
stained with Crystal Violet (0.1%). The 50% tissue culture
infectious dose (TCID50) was calculated using the method of
Reed and Muench [31].
HCV genotype 2a. Genotype 2a virus J6/JFH-1 [2] was
provided by C.M. Rice (Rockefeller University, NY) and was
titrated by an end-point dilution assay in 96-well plates. Briefly,
virus inocula were serially diluted and used to infect 8 replicate
wells of naı ¨ve Huh7.5 cells growing in microtiter plates. Four dpi,
the cells were washed, fixed with cold methanol, probed with a
mouse anti-NS5A antibody (Abcam, Cambridge, MA) and a
fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG
(H+L) (KPL Inc., Gaithersburg, MD), and finally quantitated
using an indirect immunofluorescence assay (see below) [59]. Wells
were scored positive if at least 1 positive cell was detected. The
TCID50 was calculated using the method of Reed and Muench
[31]. This procedure was followed for the experiments shown in
Figures 3B and 5D. Alternatively, stained foci were counted in
triplicate wells (Figures 4D and F), and titers were calculated as
the mean number of foci per ml (FFU/ml).
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Virus stocks for J6/JFH-1 were prepared by inoculating 1610
8
Huh7.5 cells with 1 ml culture supernatant (10
3 FFU/ml) in
serum-free medium [2]. Inoculated cells were grown at 37uC for
12 days. Filter-clarified culture supernatants were obtained as
described above. LB-piVe stocks were prepared by growing the
persistently infected cells for 8 days at 37uC in T75 flasks and
supernatants were collected as for J6/JFH-1.
Evaluation of infected cultures
Indirect immunofluorescence assays. Mock- and HCV-
infected cells grown in eight-well Permanox chamber slides (Nunc
Inc., Denmark) at 37uC were washed with PBS, fixed with cold
acetone for 30 min, and air dried. After incubation with 2% fetal
bovine serum in PBS (to block nonspecific binding), cells were
probed with mouse anti-NS5A antibodies (Abcam, Cambridge,
MA), anti-Core monoclonal antibodies (Affinity Bioreagents,
Golden, CO) or Ch1536 serum [30], followed by washing and
staining with FITC-conjugated goat anti-mouse IgG (H+L). Slides
were mounted with VECTASHIELD mounting medium (Vector
laboratories, Burlingame, CA) containing 49, 6-diamindino-2-
phenylindole (DAPI). Fluorescent micrographs were taken with a
Zeiss Axiovert microscope at a magnification of 2006(Figures 2A
and B; 3G; 4C) or 10006(Figures 1A–G; 2C; 4A and B) with
an oil-immersion objective.
Western blot analysis. To detect intracellular NS5A, 3610
6
infected cells were lysed in 0.2 ml lysis buffer [50 mM Tris, pH 8;
150 mM NaCl; 1% Nonidet P-40; 0.5% Deoxycolate; 0.1% (w/v)
sodium dodecyl sulfate (SDS)] containing protease inhibitors
(Complete protease inhibitor cocktail; Roche Applied Science,
Indianapolis, IN). Cell extracts were clarified by centrifugation,
denatured by boiling in Tris-Glycine-SDS sample buffer [60] and
resolved on Novex 4–20% Tris-glycine polyacrylamide gels
(Invitrogen, Carlsbad, CA) using Tris-Glycine-SDS running
buffer [60]. Subsequently, proteins were transferred to Hybond
ECL membranes (Amersham, Piscataway, NJ). Membranes were
incubated with PBS containing 5% (w/v) nonfat milk and 0.05%
Tween-20 (polyoxyethylene sorbitan monolaurate) to reduce
nonspecific binding, and then probed with anti-HCV NS5
antibody (Austral Biologicals, San Ramon, CA, at 1:1000), or
anti-glyceraldehyde-3-phosphate dehydrogenase antibody
(GAPDH, Trevigen, Gaithersburg, MD, at 1:3,000). After
washing with PBS-tween, membranes were probed with horse
radish peroxidase-conjugated secondary antibodies (Kirkegaard &
Perry Laboratories, Inc, Gaithersburg, MD), and antigens were
detected with SuperSignal West Femto Maximum Sensitivity
Substrate (Pierce, Rockford, IL).
Cell panning. Polystyrene petri dishes were coated overnight
with a 2.5 mg/ml solution of Anti-Human Fc antibodies (KPL
Inc., Gaithersburg, MD) in 0,05M Tris-HCl pH=9.5. Dishes
were then washed 3 times with PBS, and incubated 1 hr at room
temperature (RT) with a 1:1000 dilution of an experimental 5%
immunoglobulin intravenous (IGIV) preparation made from of
anti-HCV positive plasma (HCIGIV) or a 5% IGIV preparation
made from anti-HCV negative plasma donations [35]. LB-piVe
cells were grown for 5 days in a T150 flask, and then detached by
incubation with 0.5 mM EDTA in PBS at 37uC for 30 min. After
centrifugation, cells were washed, resuspended in 10 ml of PBS
containing 5% FBS and distributed into the panning plates.
Following an incubation of 2 hr at RT which allowed antigen-
expressing cells to attach, the plates were washed three times
gently with PBS/5% FBS and recovered and grown in complete
10% FBS DMEM supplemented with non-essential amino acids
(Invitrogen, Carlsbad, CA). This protocol was performed 3
consecutive times.
LB-piVe sequence analysis. LB-piVe filter-clarified culture
supernatants (300 ml; prepared as described above) were used to
extract viral RNA with Trizol LS (as per the manufacturer’s
directions; Invitrogen, Carlsbad, CA) followed by alcohol
precipitation. cDNA was synthesized using primer 9325R (59-
TAGGCACCACATGAACCAG-39) and AffinittyScript Multiple
Temperature Reverse Transcriptase (Stratagene, La Jolla, CA) for
one hour at 55uC followed by 15 minutes at 70uC. A first round
PCR product was generated with primers (300 nM each) 6038S
(59-CAGCAATACTGCGTCGGCACGT-39) and D1-1R (59-
TTCTTGGATTTCCGCAGGATCTCC-39) using TaKaRa LA
Taq HS (Clontech Laboratories, Inc., Madison, WI) with the
following parameters: 2 minutes at 95uC, 40 cycles with
30 seconds at 95uC, 1 minute at 53uC, 3 minutes at 72uC, and
a final extension of 10 minutes at 72uC. For the nested-PCR, 5 ml
(1/10) of the first PCR sample was added to a new tube containing
45 ml of TaKaRa LA Taq HS PCR reaction mixture and primers
(300 nM each) 6144S (59-CACTATGTGCCTGAGAGCGAC-
GCC-39) and D1-2R (59-TCTCTGACTCCACGCGGGTG-
ATGT-39). The reaction was carried out using the following
parameters: 2 minutes at 95uC, 40 cycles with 30 seconds at 95uC,
1 minute at 56uC, 3 minutes at 72uC, and a final extension of
10 minutes at 72uC. The PCR product was gel purified by using
the NucleoSpinR Extract II kit ( Macherey-Nagel, Inc. Easton,
PA) and sub-cloned into pCRII-TOPO (Invitrogen, Carlsbad,
CA). After transformation of E. coli competent bacteria, 10 clones
were selected. Both strands of the cloned-PCR product were
subjected to direct sequencing by using M13 Forward and Reverse
primers. Sequencing reactions were performed with the ABI Prism
BigDye Terminator version 3.1 Cycle-Sequencing Kit (Applied
Biosystems, Foster City, CA) according to the manufacturer’s
protocol and analyzed by using the ABI Prism 3100 system
(Applied Biosystems, Foster City, CA). Sequences have been
deposited into the National Center for Biotechnology Institutes
GenBank.
Real-time PCR assays
Determination of HCV RNA titers in filter-clarified
culture supernatants. Viral RNA was extracted from 300 ml
of LB-piVe filter-clarified culture supernatants (prepared as described
above) with Trizol LS (as per the manufacturer’s directions;
Invitrogen, Carlsbad, CA), followed by alcohol precipitation. RNA
was quantitated using a NanoDrop 1000 Spectrophotometer
( T h e r m oF i s h e rS c i e n t i f i cI n c . ,W a l t h a m ,M A ) .c D N Aw a s
synthesized using primer 200R (59-CAAGAAAGGACCCGG-
TCGTC-39) and AffinittyScript Multiple Temperature Reverse
Transcriptase (Stratagene, La Jolla, CA) for one hour at 42uC
followed by 15 minutes at 70uC. cDNA samples were tested in
triplicateina25 mlreaction. Reactions contained 5 mlc D N A ,P r e mi x
ExTaqreactionmixture(ClontechLaboratories,Inc.,Madison,WI),
300 nM each of primers 124S (59-CCCTCCCGGGAGAGCCA-
TAG-39) and 200R, and 200 nM of probe (6FAM- 59-TCTGC-
GGAACCGGTGAGTACACC-39-TAMRA, Applied Biosystems,
Foster City, CA). Real-time PCR analysis was performed in an ABI
7300 Sequence Detection System as follows: 1 minute at 95uC, 5
cycles with 20 seconds at 95uCa n d1m i n u t ea t6 0 uC, 40 cycles with
20 seconds at 95uC, 30 seconds at 60uCa n d3 1s e c o n d sa t7 2 uC.
RNA standards, run in triplicate, were prepared as described
previously [61].
Determination of HCV RNA titers in cell extracts. Total
cellular RNA was extracted from approximately 10
6 infected
Huh7.5 or VeroE6 cells, using the RNeasy minikit, following the
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quantitated using a NanoDrop 1000 Spectrophotometer (Thermo
Fisher Scientific Inc., Waltham, MA). RNA was analyzed by RT-
PCR using primers in the HCV 59 end extending to the Core area
[62]. Determination of HCV RNA titers in cells infected with
genotype 1b plasma (LB) was performed by real-time RT-PCR
analysis as described previously [63]. HCV RNA titers in J6/JFH-
1 infected cells were quantitated following identical procedures as
for LB, but using a fluorescent probe (FAM-labeled) coding for
nucleotides 335–358 designed from published sequences [63].
Relative quantitation of HCV RNA was performed with the
Comparative CT Method, using glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) as endogenous control, following the
manufacturer’s protocols and recommendations (Applied
Biosystems, Foster City, CA).
Inhibition of infection by anti-CD81 antibodies
Huh7.5 cells were plated at a density of 5610
3 per well in 96-
well plates to obtain 60% confluence after 24 hr. Cells were
incubated with anti-CD81 (BD Pharmingen, San Diego, CA) or
isotype-matched control anti-flag M2 (Sigma, St. Louis, MO)
antibodies for 1 hr at 37uC.and subsequently infected with serial
dilutions of J6/JFH-1 or LB-piVe filter-clarified supernatants.
After 6 hr at 37uC, cells were washed and supplemented with fresh
media. Three dpi, J6/JFH-1-infected cells were immunostained
with anti-Core antibodies [59]. Wells were scored positive if at
least 1 positive cell was detected. LB-piVe-infected cells were
observed by light microscopy at 5 dpi. Wells showing CPE were
assigned a positive result and titers were calculated as described
above.
Neutralization of LB-piVe by anti-E2 antibodies and HCV-
specific immunoglobulins (HCIGIV)
8610
2 TCID50 LB-piVe were treated for 1hr at 37uC with 5-
fold dilutions of a cocktail of anti-E2 monoclonal antibodies [36]
or 5mg/ml of isotype-matched control anti-flag M2 (Sigma, St.
Louis, MO) antibody. The anti-E2 monoclonal antibodies were
produced by hybridomas obtained after immunization of BALB/c
mice with E1 and E2 glycoproteins expressed in insect cells [36].
Huh7.5 cells growing in 96-well plates were inoculated with serial
dilutions of the neutralization reaction products and incubated for
5 days. LB-piVe titers were determined by a CPE-based end-point
dilution assay. To test LB-piVe virus neutralization by immuno-
globulins prepared from human plasma, virus was incubated with
HCIGIV [35] or HCV-negative IGIV [35], before titrating on
naı ¨ve Huh7.5 cells.
Inhibition of viral replication with 29-C-Methyl-D-
Adenosine
29-C-Methyl-D-Adenosine (29-C-Me-A) was obtained from
Carbosynth Ltd. (Berkshire, UK) and resuspended at 100 mM
[37] in dimethylsulfoxide (DMSO). 5610
3 Huh7.5 cells were
infected with filter-clarified supernatants containing 100 FFU
of J6/JFH-1 for 12 hours, washed, and incubated with
complete growth medium containing a range of 0.05 to
1 mM2 9-C-Me-A. Three dpi, J6/JFH-1 infected cells were
immunostained with anti-Core antibodies [59]. Fluorescent
foci were counted in triplicate wells, and titers were calculated
as the mean number of foci per ml (FFU/ml). To measure
inhibition of LB-piVe growth, 5610
5 LB-piVe cells were
grown in T25 flasks. After 3 days, 29-C-Me-A was added to the
growth media and cells were incubated for 3 additional days.
Filter-clarified culture supernatants from treated LB-piVe cells
were titrated in a CPE-based end-point dilution assay as
described above. HCV growth in the absence of 29-C-Me-A
was set at 100%. The percentage reduction in the inhibitor
treated cells relative to the untreated control was plotted
against 29-C-Me-A concentrations, employing GraphPad
Prism 3.0 software. 50% effective concentration (EC50)v a l u e
values were interpolated from the resulting curves. To measure
t h el e v e lo fv i r a lR N Ai nt h ep r e s e n c eo f2 9-C-Me-A, Vero E6
cells growing in 6-well plates were transfected with either WT-
or mutant-VA RNAI. Four hours post-transfection, cells were
treated with media containing 1 mM2 9-C-Me-A overnight
and then infected with the parental LB virus. Total cellular
RNA was extracted at 0, 2, 4, 6 and 8 days post-infection.
Determination of HCV RNA titers was performed by real-time
RT-PCR analysis as described previously [62].
Inhibition of viral replication by HCV-specific siRNA
A chemically synthesized irrelevant oligo, termed siIRR [64]
[59-AAGGACUUCCAGAAGAACAUCTT-39] and an HCV-
specific oligo, termed si313 [38] [59-CCCGGGAGGUCUCGUA-
GACTT-39 ], were obtained from Dharmacon, Lafayette, CO.
Huh7.5 cells (2610
4) were transfected with 100 nM of siIRR or
si313 using DharmaFECT Transfection reagent 1 (Dharmacon,
Lafayette, CO) following the manufacturer’s protocol and
recommendations. One day after siRNA transfection, cells were
infected with 200 FFU of J6/JFH-1 or 200 TCID50 LB-piVe.
Three dpi, J6/JFH-1 infected cells were washed, fixed and stained
using an indirect immunofluorescence assay with anti-Core
antibodies [59]. Fluorescent foci were counted in triplicate wells,
and titers were calculated as the mean number of foci per ml
(FFU/ml). LB-piVe infected cells were detected by observing CPE
by light microscopy. Culture supernatants of LB-piVe infected
cells were titrated by a CPE-based end-point dilution assay on
naı ¨ve Huh7.5 cells as described above. Viral titers were calculated
using the method of Reed and Muench [31].
Inhibition of viral replication by IFN
LB-piVe cells were grown in T25 flasks at a density to provide
an overnight confluence of 40%, and transfected with pVA. One
day post-transfection, cells were treated with 0, 10, 100 and
1000 IU/ml of Universal Type 1 IFN (PBL Interferon Source,
Piscataway, NJ) for 24, 48 and 72 hr. Filter-clarified culture
supernatants were prepared and titrated by a CPE-based end-
point dilution assay on naı ¨ve Huh7.5 cells as described above.
Viral titers were calculated using the method of Reed and Muench
[31]. Alternatively, LB-piVe titers were determined in naı ¨ve
Huh7.5 in the presence of 0, 10, and 1000 IU/ml of IFN.
Effect of VA RNAI on J6/JFH-1
To show the effect of VA RNAI on J6/JFH-1, Huh7.5 cells
were transfected with plasmid vectors pVA or pVAdl [26,27], and
infected the following day with 10
5 TCID50. J6/JFH-1 (filter-
clarified culture supernatants from Huh7.5 cells that were
transfected with wild-type or mutant VA RNAI plasmids). The
infected Huh7.5 cells were titrated by end-point dilution in 96-well
plates as described above. Wells were scored positive if at least 1
positive cell was detected. The TCID50 was calculated using the
method of Reed and Muench [31].
Accession numbers
Sequences can be accessed from GenBank through the NCBI
website: H77 (AF009606); JFH-1 (AB047639); adenovirus 2
(AC000007); LB-piVe (FJ976045, FJ976046 and FJ976047).
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Figure S1 LB-piVe shares sequence homology but not identity
with prototype genotype 1b strain. Nucleotide sequence alignment
of LB-piVe derived from clones fragments amplified from
persistently infected cells. The 39-UTR amplicons derived from
each clone were sequenced bidirectionally. The HCV genotype 1b
sequence (EU155326.2) is shown on the third line. Nucleotides in
the sequences identical to those of the reference are shown in
green, similar nucleotides (purines or pyrimidines) are shown in
cyan, deletions are shown as dashes, and different nucleotides are
shown in white. Numbering of the nucleotides is according to the
EU155326.2 HCV genotype 1b sequence. LB-piVe: virus derived
from LB-piVe cells; LB: serum-derived parental virus.
Found at: doi:10.1371/journal.ppat.1000910.s001 (3.04 MB
DOC)
Table S1 HCV genotype 1a replicates in hepatic and non-
hepatic cells transfected with VA RNAI.
Found at: doi:10.1371/journal.ppat.1000910.s002 (0.07 MB
DOC)
Text S1 Hepatic and non-hepatic cells are permissive to HCV
genotype 1a infection if VA RNAI is present.
Found at: doi:10.1371/journal.ppat.1000910.s003 (0.03 MB
DOC)
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